Last reviewed · How we verify
Injected bupivacaine post-operatively
At a glance
| Generic name | Injected bupivacaine post-operatively |
|---|---|
| Also known as | bupivacaine |
| Sponsor | Pinnacle Health System |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RCT to Test Regional Anesthesia Effect on Decreased Opiate Use (PHASE3)
- Analgesic Requirements for Lumbar Fixation With General Anaesthesia Versus Continuous Caudal Epidural (NA)
- Comparison of the Efficacy of Erector Spina Plane Block and Thoracic Epidural Analgesia After Thoracotomy
- Exparel and Education to Avoid Opioids After Carpal Tunnel Release (PHASE4)
- Impact of Adductor Canal Block on Functional Recovery (NA)
- Liposomal Bupivacaine in Implant Based Breast Reconstruction (NA)
- Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty (PHASE4)
- Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injected bupivacaine post-operatively CI brief — competitive landscape report
- Injected bupivacaine post-operatively updates RSS · CI watch RSS
- Pinnacle Health System portfolio CI